FDA approves Phase II clinical study application for New Small Molecule JAK1 Inhibitor SHR0302

ulcerative colitis is an autoimmune disease, inflammatory lesions are limited to the mucous membrane of the large intestine and the lower mucous membrane, mainly ulcer erosionThe lesions may affect the entire colonrecently, theof ThePharmaceuticals of Ruishi (LimitedCompany("Ruishi"),) officially announced that the U.SFDA(approved the Company's declared application for phase II clinical study of the new small molecule JAK1 inhibitor SHR0302)about SHR0302
SHR0302 licensed by Ruishi investor Jiangsu Hengrui Pharmaceutical Co., Ltd("Hengrui"), Ruishi has global interests in addition to rheumatoid arthritis and external skin sciencethis FDA approved this product for clinical studies of ulcerative colitisChina's clinical research declaration was completed at the end of August, and the European clinical research declaration is in progressRuishi Bio
pharmaceutical co., Ltd., founded in January 2018 and headquartered in Shanghai, China, with branches in Beijing and Boston, USA, is an innovative research and development-driven global bio
pharmaceutical(the company, based on the development of clinically urgently needednew drug(materials to meet the needs of patients)at present, Ruishi focuses on the innovation of autoimmune diseasesdrug(global development, on the one hand, with the domestic leading pharmaceuticalenterprises(Hengrui cooperation to introduce China's innovative drugs into the United States and Europe, to help China's innovation to the world;